Research Article

Synne Flatlandsmo Tangen*, Anne-Sofie Helvik, Hilde Eide and Egil A. Fors

Pain acceptance and its impact on function and symptoms in fibromyalgia

https://doi.org/10.1515/sjpain-2020-0049
Received April 8, 2020; accepted June 17, 2020; published online August 7, 2020

Abstract

Objectives: Fibromyalgia is a chronic widespread pain (CWP) syndrome of unknown etiology with substantial burden of illness and functional impairment. Pain acceptance has emerged as an interesting target of therapy in chronic pain populations, but few studies have yet been done on the effect of pain acceptance on patients with fibromyalgia. The aim of the present study was to examine the relationship between pain acceptance and its impact on function and symptoms in fibromyalgia with both a cross-sectional and longitudinal design.

Methods: Three hundred and sixty five participants aged 22–70 with fibromyalgia were recruited from the Norwegian Fibromyalgia Association (NFA). They filled out a questionnaire containing the Fibromyalgia Impact Questionnaire (FIQ), measurement of function and symptoms, and Chronic Pain Acceptance Questionnaire (CPAQ), measurement of pain acceptance, in addition to socio-demographic and clinical variables such as degree of fibromyalgia, depression and pain duration (T1 measures). One year after, 87 of the participants filled out the FIQ and clinical measures once again (T2 measures). Unadjusted and adjusted linear regression analyses were performed both for cross-sectional measures at T1 and for longitudinal measures from T1 to T2, with FIQ score as the outcome variable and CPAQ score at T1 as one of the main independent variables.

Results: Higher CPAQ score was significantly associated with a lower FIQ score at T1, also when adjusting for age, education, work, depression and Fibromyalgianess Score (p<0.01). Lower FIQ score indicate less impact of fibromyalgia on functioning. In addition, two adjusted linear regression models found higher pain acceptance (CPAQ score) at T1 to be associated with lower negative impact of fibromyalgia on function and symptoms (FIQ score) at T2 (p<0.01).

Conclusions: Higher pain acceptance is associated with better functional level and less symptoms in fibromyalgia, both cross-sectionally and when measurements are separated in time. Further research should include experimental studies with acceptance-based interventions for this patient group.

Keywords: fibromyalgia; function; longitudinal; Norwegian Fibromyalgia Association; pain acceptance.

Introduction

Fibromyalgia is a chronic wide-spread pain syndrome, also characterized by fatigue, sleep disturbances, cognitive dysfunction, depressive symptoms, headache and irritable bowel [1–4]. Other comorbid medical symptoms such as dysmenorrhea, temporomandibular joint disorder and anxiety are common [5] along with more than 40 medical unexplained symptoms [6]. Diagnostic criteria were established by the American College of Rheumatology in 1990 [7] with revisions in 2010/2011 [1, 6] and 2016 [8].

The global prevalence of the condition lies between 0.2 and 6.6% [9] with a female majority. Traditionally, treatment paradigms of chronic pain have assumed that the primary aims should be reduced pain and increased control over responses to pain [10]. However, this may not always be possible to achieve, nor result in better functioning and quality of life. In general, the effect sizes for most established treatments are modest, but recently the European League Against Rheumatism have recommended a multidisciplinary step-by-step

*Corresponding author: Synne Flatlandsmo Tangen, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 4791 Trondheim, Norway, Phone: +47 95364550, E-mail: synneft@stud.ntnu.no
Anne-Sofie Helvik and Egil A. Fors: Faculty of Medicine and Health Sciences, Department of Public Health and Nursing, General Practitioner Research Unit, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, E-mail: anne-sofie.helvik@ntnu.no (A.S. Helvik), egil.a.fors@ntnu.no (E.A. Fors)
Hilde Eide: Science Centre Health and Technology, Faculty of Health and Social Sciences, University of South-Eastern Norway, Drammen, Norway, E-mail: Hilde.Eide@usn.no

Open Access. © 2020 Synne Flatlandsmo Tangen et al., published by De Gruyter. This work is licensed under the Creative Commons Attribution 4.0 International License.
Materials and methods

Design and participants

The study has a longitudinal design reporting on a cross-sectional sample at T1 with a follow-up of a subsample (T2) after one year (see Figure 1). In total, 399 patients diagnosed with fibromyalgia were recruited from 1,033 eligible members of the Norwegian Fibromyalgia Association (NFA) from all regions in Norway. Inclusion criteria were patients aged 18–70 with a former fibromyalgia diagnosis marked with a “yes” on the question “Do you have or had previously fibromyalgia?” (Derived from the Nord-Trøndelag Health Study, HUNT 3) [28]. Of the 399, five were excluded because of lacking information or “no” at the question of a fibromyalgia diagnosis (n=394). Another 29 were excluded because of age over 70 years old, leaving a total of 365 respondents in the T1 group (see Figure 1). One year after, 144 of the NFA members from the Trondheim region or from Bergen were asked to participate in a second assessment. Of these, 91 agreed to the follow-up. Four participants were excluded because of age over 70, leaving a total of 87 respondents from baseline to be included at T2.

Measures

Pain acceptance: The Chronic Pain Acceptance Questionnaire-20 (CPAQ-20) [21, 29] was used to measure pain acceptance once (T1). CPAQ is widely used in pain research and considered to be a valid measure of pain acceptance. It is a 20-item descriptive scale and self-report questionnaire designed to assess the two core aspects of pain acceptance: Activity engagement (to which degree the respondent manages to participate in daily activities despite pain) and pain willingness (the ability to experience pain without trying to control, change or avoid it). A seven-point Likert scale is used, from 0 (never true) to 6 (always true). Nine of the items are scored inversely, and together they make up the Pain Willingness Score (PWS). Eleven items are scored directly to make up the Activity Engagement Score (AES). The total score (CPAQ) is the sum of PWS and AES, and ranges from 0 to 120. Higher score reflects higher acceptance of pain and higher participation in activities. The internal consistency of the Norwegian version of CPAQ-20 [29] is previously found adequate (Cronbach’s alpha of 0.85) and in line with international studies (Cronbach’s alpha of 0.82) [21]. In this study, Cronbach’s alpha for CPAQ was 0.88.

Fibromyalgia Impact: The Fibromyalgia Impact Questionnaire (FIQ) was used at two time-points to examine the impact of fibromyalgia on function and level of symptoms through the last week [30]. It is one of the most widely used specific questionnaires in fibromyalgia studies, comprising 10 items (20 questions) which are computed into an FIQ function score, FIQ overall impact score and an FIQ symptom score. FIQ total is the sum score of all 10 items, with 100 as its maximum. Higher scores indicate greater impact of fibromyalgia on functioning. The FIQ evaluates the total spectrum of fibromyalgia-related problems [31]. It has been shown to have credible construct validity, reliable test-retest characteristics and a good sensitivity to appropriate clinical change [32, 33]. A Norwegian direct translation of the English 2002 version was used in this study. The newer, revised FIQ version, FIQ-R, is not translated into Norwegian. Internal consistency for FIQ total at baseline, measured by Cronbach’s alpha, was 0.58.
**Depression:** Depression was examined twice using a single-item screening question. The respondents stated how much sadness or depressive symptoms they had been experiencing the last 30 days. The answers were given on a 4-point Likert scale ranging from 0 = “not at all”; 1 = “a little”; 2 = “some”; 3 = “serious”. For analysis purposes the scale was dichotomized into 0 = “no or a little”, 1 = “some or serious”.

In a Norwegian study, the single-item depression screening has shown a sensitivity of 95% and specificity of 56% compared to an MINI interview as the gold standard [34].

**Fibromyalgianess Scale:** The Fibromyalgianess Scale, also known as the Fibromyalgia Symptom Scale or Polysymptomatic Distress Scale, was used to measure the degree of illness at two time-points. It is made up of the Widespread Pain Index (WPI) and Symptom Severity Scale (SSS), both of which are core measurements in the revised diagnostic criteria for fibromyalgia [4]. The maximum score of SSS is 12 and the maximum score of WPI is 19, making the maximum score of the Fibromyalgianess Scale 31. Internal consistency for the Fibromyalgianess Scale at baseline, measured by Cronbach’s alpha, was 0.765.

**Pain duration:** Pain duration was assessed once (T1). Responses were given on an ordinal scale with eight response options ranging from “0–3 months” up to “more than 10 years”. Based on sample characteristics, the scale was dichotomized for analysis purposes to “≤10 years” or “>10 years”. A similar approach has been used in other fibromyalgia studies [35].

**Socio-demographic information:** Socio-demographic characteristics were assessed once (T1). Marital status was addressed using one item

---

**Figure 1:** Design and participants.
Results

Characteristics of participants

In the cross-sectional study at T1, 365 (354 women, 97%) participated, with a mean (SD) age of 54 (±9.9) years, ranging from 22 to 70 years (see Table 1). In total, more than one quarter of the participants (102/365, 28%) reported quite a lot or serious depressive symptoms during the last 30 days and three quarter of the participants (284/365, 77.8%) reported their pain to have lasted more than 10 years. There were no baseline significant differences between the participants assessed only once (T1, group A) and those being assessed twice (T1 and T2, group B) regarding neither sociodemographic nor clinical variables.

Pain acceptance and fibromyalgia impact — the cross-sectional study at T1

For the total sample, the mean (SD) score of the CPAQ and FIQ total was 63.30 (17.11) and 50.58 (13.458), respectively. The linear regression analysis adjusting for age, education, work, depression and Fibromyalgianess Score found higher pain acceptance (CPAQ score) to be significantly associated with lower negative impact of fibromyalgia on function and symptoms (FIQ score) (p<0.01) (Table 2). The adjusted explained variance in the model was 46.5%.

Pain acceptance and fibromyalgia impact — the longitudinal study (T1-T2)

The participants with longitudinal data (Group B) had a reduced mean of FIQ total at T2 (mean 49.23, SD 13.23 at T1 vs. mean 46.23, SD 11.99 at T2, p=0.01) (Table 3), with an absolute mean reduction of three FIQ points (−3.8%). Two adjusted linear regression models found higher pain acceptance (CPAQ score) at T1 associated with lower negative impact of fibromyalgia on function and symptoms (FIQ score) at T2 (Table 4). The adjusted explained variance for Model 1 and Model 2 were 45.9 and 47.0%, respectively.

Discussion

This study shows that higher pain acceptance is associated with better daily functional level and less pain and other co-occurring symptoms in patients with fibromyalgia. The positive effect of acceptance remains significant also when adjusting for potentially relevant factors. The cross-sectional findings are consistent with results from previous studies [12, 17, 24, 25, 27, 36, 37] and adds to the evidence that pain acceptance plays a part in patients with fibromyalgia as well as in other patients with chronic pain. However, the longitudinal sub-study is the first of its kind in patients with fibromyalgia. It shows that higher pain acceptance is significantly associated with better functional level and symptoms also when measurements are stretched out in time, i.e., one year. A similar study design was used in a longitudinal study on pain acceptance and patient functioning in persons with chronic pain by McCracken and Eccleston [20], where the time between assessments was in average 4 months (range 0.5–15.0 months). In a sample of 118 patients with chronic pain, higher acceptance of pain was found to be associated with better emotional, physical, and social functioning and less
use of medication. McCracken and Eccleston argues that pain level, mood or social setting at the time of assessment potentially influence the way a patient responds to self-report questionnaires. This may lead them to answer consistently on separate measures even though such a consistency does not reflect reality. Through choosing a longitudinal approach and extending measurements in time, these potential influences are minimized. The fact that relations between CPAQ score and FIQ score can be reproduced also after one year, therefore strengthens the evidence of the relation between acceptance and impact of illness.

Sociodemographic features of the participants in the cross-sectional study are consistent with observations from previous research of patients with fibromyalgia [38–41]. In the cross-sectional study, higher age, high educational level, work, no depression and lower degree of illness (Fibromyalgianess Score) were found to be associated with the outcome, lower FIQ score, i.e., better daily functional level and lower symptoms in patients with fibromyalgia. Previous studies have identified high age, low educational level and low socioeconomic status as associative factors for fibromyalgia [39, 41], and depression has been found to be a common comorbidity as well as associated with a higher impact of the illness [42].

Table 1: Sample characteristics at T1 (N=365).

| Gender             | Total  | Group A (tested at T1 only) | Group B (tested both at T1 and T2) | p-Value* |
|--------------------|--------|-----------------------------|-----------------------------------|----------|
|                    | 365 (100) | 278 (76.2) | 87 (23.8) | A vs. B b,c,d |
| Gender             | n (%)  | (tested at T1 only) | (tested both at T1 and T2) | p-Value* |
| Male               | 11 (3.0) | 10 (3.6) | 1 (1.1) | 0.24 b |
| Female             | 354 (97.0) | 268 (96.4) | 86 (98.9) | 0.19 c |
| Age                | Mean (SD) | 54.03 (9.94) | 54.40 (9.93) | 52.86 (9.94) | 0.19 c |
| Marital status     |        |              |                          |          |
| With partner       | n (%)  | 281 (77.0) | 218 (78.4) | 63 (72.4) | 0.25 b |
| Without partner    | n (%)  | 84 (23.0) | 60 (21.6) | 24 (27.5) | 0.25 b |
| Education          |        |              |                          |          |
| Lower education    | n (%)  | 136 (37.3) | 101 (36.4) | 35 (40.2) | 0.51 b |
| Higher education   | n (%)  | 229 (62.7) | 177 (63.7) | 52 (59.7) | 0.51 b |
| Currently working e|        |              |                          |          |
| No current work    | n (%)  | 182 (49.9) | 131 (47.1) | 51 (58.6) | 0.08 b |
| Work or under education | n (%)  | 178 (48.8) | 142 (51.1) | 36 (41.4) | 0.08 b |
| Depression e       |        |              |                          |          |
| No or a little     | n (%)  | 259 (71.0) | 192 (69.0) | 67 (77.0) | 0.21 b |
| Some or serious    | n (%)  | 102 (28.0) | 82 (29.5) | 20 (23.0) | 0.21 b |
| Pain duration      |        |              |                          |          |
| ≤10 years          | n (%)  | 81 (22.2) | 63 (22.7) | 18 (20.7) | 0.67 b |
| >10 years          | n (%)  | 284 (77.8) | 215 (77.3) | 69 (79.3) | 0.67 b |
| Fibromyalgianess e | 0–31   | Mean (SD) | 20.25 (5.29) | 20.28 (5.18) | 20.12 (5.67) | 0.86 c |
|                    | 0–12   | Mean (SD) | 8.11 (2.28) | 8.16 (2.31) | 7.95 (2.20) | 0.86 c |
|                    | 0–19   | Mean (SD) | 12.09 (3.89) | 12.07 (3.77) | 12.17 (4.29) | 0.71 c |
|                    | 0–120  | Mean (SD) | 63.30 (17.11) | 63.19 (17.02) | 63.64 (17.47) | 0.84 d |
|                    | 0–66   | Mean (SD) | 36.51 (10.98) | 36.41 (11.06) | 36.83 (10.75) | 0.75 d |
|                    | 0–54   | Mean (SD) | 26.53 (8.72) | 26.43 (8.73) | 26.82 (8.73) | 0.73 d |
|                    | 0–100  | Mean (SD) | 50.58 (13.76) | 51.00 (13.92) | 49.23 (13.23) | 0.28 d |
|                    | 0–10   | Mean (SD) | 3.26 (1.94) | 3.31 (1.96) | 3.09 (1.89) | 0.45 c |
|                    | 0–20   | Mean (SD) | 5.67 (3.63) | 5.79 (3.54) | 5.30 (3.90) | 0.14 c |
|                    | 0–70   | Mean (SD) | 41.82 (12.08) | 42.06 (12.33) | 41.06 (11.32) | 0.49 d |

a p-Values for comparison of groups at baseline.
b Calculated using Chi-square test for categorical data.
c Calculated using Mann-Whitney test for non-parametric variables.
d Calculated using independent samples T-test for parametric variables.
e Do not sum up to 365 due to missing information (5 missing for current work; four missing for depression; 18 missing for Fibromyalgianess and SSS; 26 missing for CPAQ and PWS; two missing for FIQ overall impact; 12 missing for FIQ symptoms).

SSS, Symptom Severity Score; WPI, Widespread Pain Index; CPAQ, Chronic Pain Acceptance Questionnaire; AES, Activity Engagement Score; PWS, Pain Willingness Score; FIQ, Fibromyalgia Impact Questionnaire.
Table 2: Linear regression of T1 measures with FIQ as outcome variable.

|                          | Unadjusted Unstandardized B (95% CI) | Standardized β | p-Value | Adjusted Unadjusted Unstandardized B (95% CI) | Standardized β | p-Value |
|--------------------------|--------------------------------------|----------------|---------|---------------------------------------------|----------------|---------|
| Age in years             | −0.28 (−0.42; −0.14)                 | −0.20          | <0.01   | −0.23 (−0.35; −0.11)                        | −0.16          | <0.01   |
| Higher education (vs. lower) | −3.90 (−6.80; −0.99)               | −0.14          | <0.01   | −2.78 (−5.17; −0.38)                        | −0.10          | 0.02    |
| Current working (vs. not) | −7.21 (−9.97; −4.45)                 | −0.26          | <0.01   | −5.22 (−7.62; −2.83)                        | −0.19          | <0.01   |
| With partner (vs. without) | −0.45 (−3.82; 2.92)                 | −0.01          | 0.80    |                                             |                |         |
| Pain duration >10 years (vs. not) | 0.82 (2.59; 4.23)            | 0.03           | 0.64    |                                             |                |         |
| Fibromyalgianess         | 1.24 (1.0; 1.49)                    | 0.48           | <0.01   | 0.69 (0.46; 0.92)                           | 0.26           | <0.01   |
| Depression (vs. not)     | 12.68 (9.97; 15.57)                 | 0.41           | <0.01   | 7.39 (4.83; 9.96)                           | 0.24           | <0.01   |
| CPAQ                     | −0.41 (−0.48; −0.34)                | −0.52          | <0.01   | −0.26 (−0.33; −0.20)                        | −0.33          | <0.01   |
| Adjusted R²              |                                      |                |         | 0.465                                       |                |         |

aN=315.

Table 3: T2 repeated measures with comparison from T1 (N=87).

|                          | Group B 87 (23.8) | p-Value B T1 vs. B T2<sup>a,b</sup> |
|--------------------------|------------------|--------------------------------------|
| n (%)                    |                  |                                      |
| No or a little < n (%)   | 71 (81.6)        | 0.146<sup>a</sup>                    |
| Quite a lot or ≥ n (%)   | 14 (16.1)        |                                      |
| Fibromyalgianess<sup>d</sup> |                  |                                      |
| 0–31 Mean (SD)           | 19.83 (5.05)     | 0.20<sup>b</sup>                     |
| SSS<sup>d</sup>          |                  |                                      |
| 0–12 Mean (SD)           | 7.76 (2.25)      | 0.08<sup>b</sup>                     |
| WPI                      |                  |                                      |
| 0–19 Mean (SD)           | 11.93 (4.02)     | 0.47<sup>b</sup>                     |
| FIQ total                |                  |                                      |
| 0–100 Mean (SD)          | 46.23 (11.99)    | 0.01<sup>b</sup>                     |
| FIQ function<sup>d</sup> |                  |                                      |
| 0–10 Mean (SD)           | 2.74 (1.91)      | 0.02<sup>b</sup>                     |
| FIQ overall impact<sup>d</sup> |                |                                      |
| 0–20 Mean (SD)           | 5.69 (3.78)      | 0.74<sup>c</sup>                     |
| FIQ symptoms<sup>d</sup> |                  |                                      |
| 0–70 Mean (SD)           | 37.69 (10.56)    | <0.01<sup>b</sup>                    |

<sup>a</sup>Calculated using McNemar’s test for related samples.
<sup>b</sup>Calculated using paired t test.
<sup>c</sup>Do not sum up to 87 due to missing information (two missing for depression; four missing for Fibromyalgianess and SSS; one missing for FIQ function; two missing for FIQ overall impact).
<sup>d</sup>SSS, Symptom Severity Score; WPI, Widespread Pain Index; FIQ, Fibromyalgia Impact Questionnaire.

In addition, the follow-up time was only one year, not a long time in the perspective of chronic illness (most of the respondents, 77.8%, had been ill for more than 10 years). Pain is considered to be rather stable over time in chronic pain populations, with day-to-day fluctuations in function and impairment rather than large changes over time [44, 45].

### Strengths and limitations

Some apparent strengths are that the sample size of the cross-sectional study is relatively large, and the longitudinal design with a follow-up group providing repeated measures makes this study different than previous studies on the topic. Fibromyalgia is a condition not yet fully understood, and it is of great clinical interest to find out more about the factors influencing this condition in order to better help a patient group who suffers a large burden of illness [46]. The questionnaires used, FIQ and CPAQ, are established as valid measures internationally and are widely used in fibromyalgia research. However, FIQ has been revised, but this newer FIQ-R version is not translated into Norwegian. Nevertheless, according to Bennett et al. the FIQ revised (FIQ-R) has a good correlation with the original FIQ, thus providing the ability to compare the results of studies using the older version with studies using the revised version [47].

Participants in the cross-sectional study were from all regions of Norway, both urban and rural areas, thus strengthening the assumption that the respondents are representative for the fibromyalgia population in the country. Due to practical reasons, respondents in the follow-up group were from the Trondheim and Bergen regions only. However, the follow-up group did not differ

The mean values of FIQ total do not change substantially from T1 to T2. Minimal clinically important difference (MCID) in FIQ is estimated to be around 14% [43], but the mean values changed much less here, with only a 3% reduction from T1 to T2. The lack of change could be expected, given the fact that no intervention was introduced.
Table 4: Linear regression of longitudinal measures (T1-T2) with FIQ at T2 as outcome variable.

|                          | Unadjusted |                          | Adjusted |                          | Adjusted |
|--------------------------|------------|--------------------------|----------|--------------------------|----------|
|                          | Unstandardized B (95% CI) | Standardized β | p-Value | Unstandardized B (95% CI) | Standardized β | p-Value |
| Age in years             | -0.36 (-0.61; -0.112)     | -0.30          | <0.01   | -0.07 (-0.28; 0.15)      | -0.06      | 0.54    |
| Higher education (vs. lower) | -2.94 (-8.15; 2.26)     | -0.12          | 0.26    |                          |           |        |
| Current working (vs. not) | -2.67 (-7.86; 2.52)      | -0.11          | 0.31    |                          |           |        |
| With partner (vs. without) | -5.18 (-10.83; 0.46)    | -0.19          | 0.07    | -2.88 (-7.29; 1.56)      | -0.11      | 0.20    |
| Pain duration > 10 years (vs. not) | -1.45 (-7.79; 4.89)   | -0.05          | 0.65    |                          |           |        |
| Fibromyalginess           | 0.62 (0.16; 1.07)        | 0.29           | <0.01   | 0.14 (-0.26; 0.53)       | 0.06      | 0.49    |
| FIQ total T1              | 0.57 (0.08; 0.42)        | 0.63           | <0.01   | 0.38 (0.19; 0.56)        | 0.41      | <0.01   |
| Depression (vs. not)      | 10.20 (4.49; 15.90)      | 0.36           | <0.01   | 5.61 (0.75; 10.48)       | 0.20      | 0.02    |
| CPAQ                      | -0.33 (-0.46; -0.20)     | -0.48          | <0.01   | -0.18 (-0.31; -0.06)     | -0.27     | <0.01   |

Adjusted R²: 0.472

n=81.

n=83.
respondents would satisfy the clinical diagnostic criteria, given that we lack information about their diagnostic work-up. The epidemiological approach for inclusion was chosen because this study is based on the same data collection as an ongoing validation study of the revised 2016 diagnostic criteria [50].

Further perspectives

Acceptance of pain is a key aspect in pain management, important for functioning as well as possible when you have a chronic pain disease. More knowledge of these potential positive effects among clinicians when meeting patients with fibromyalgia is crucial. Through this, clinicians can educate their patients on the benefits of “letting the pain be pain”, trying not to fight it but attempting to continue with meaningful daily activities despite their chronic illness. Future research could preferable include more male fibromyalgia patients, since the predominance of females in previous studies is large and does not reflect what is now believed to be the true gender distribution in纤维肌痛。In an unbiased study using the 2016 diagnostic criteria, the female proportion was found to be less than 60% [51].

To further explore the potential clinical benefits of acceptance in fibromyalgia, the next natural step would be a randomized controlled trial (RCT) with an acceptance-based therapy as the intervention. A systematic review from 2019 on mindfulness- and acceptance-based therapy for fibromyalgia included three such RCTs in their meta-analyses [52]. All of them had an Acceptance and Commitment Therapy (ACT) program as intervention, and measured FIQ. Two of the studies also measured CPAQ [53, 54]. These two showed a relatively large effect size on FIQ reduction in the intervention group compared to treatment as usual, as well as an increase in CPAQ. However, study samples were small, and the systematic review concludes that the effect of acceptance-based interventions in fibromyalgia is promising, but uncertain. Further research is therefore warranted, with robust intervention-based study designs and adequately large study samples.

Conclusion

This study shows that higher pain acceptance is associated with better functional level and less symptoms in fibromyalgia patients, both cross-sectionally and when measurements are separated in time. Our cross-sectional results are consistent with previous research on fibromyalgia populations and adds to the body of evidence that pain acceptance plays a key role in day-to-day function for this patient group. The longitudinal analysis strengthens this assumption even further. Future research should include intervention-based studies with ACT or other acceptance-related therapies as target of intervention.

Research funding: General Practitioner Research Unit, NTNU, Trondheim, Norway; Norwegian Fibromyalgia Association (NFA).

Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Competing interests: All authors and contributors state that there are no conflicts of interest.

Informed consent: All participants signed an informed consent, either electronically or on paper, before inclusion.

Ethical approval: The study was approved by the Regional Committee for Medical and Health Research Ethics (project REK Nord # 2014/938), including fulfillment of the General Data Protection Regulation and in accordance with the Declaration of Helsinki.

References

1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011;38:1113–22.
2. Ghiggia A, Romeo A, Tesio V, Tella MD, Colonna F, Geminiani GC, et al. Alexithymia and depression in patients with fibromyalgia: When the whole is greater than the sum of its parts. Psychiatr Res 2017;255:195–7.
3. Castelli L, Tesio V, Colonna F, Molinaro S, Leombruni P, Bruzzone M, et al. Alexithymia and psychological distress in fibromyalgia: prevalence and relation with quality of life. Clin Exp Rheumatol 2012;30 (6 Suppl 74):70–7.
4. Fietta P, Fietta P, Manganelli P. Fibromyalgia and psychiatric disorders. Acta Biomed 2007;78:88–95.
5. Clauw DJ. Fibromyalgia a clinical review. JAMA, J Am Med Assoc 2014;311:1547–55.
6. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600–10.
7. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The american college of rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990;33:160–72.
8. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319–29.
9. Marques AP, Santo AdSdE, Berrsanetti AA, Matsutani LA, Yuan SLK. Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol (English Edition) 2017;57:356–63.
10. Kratz AL, Davis MC, Zautra AJ. Pain acceptance moderates the relation between pain and negative affect in female osteoarthritis and fibromyalgia patients. Ann Behav Med 2007; 33:291–301.
11. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017;76:318–28.
12. McCracken LM. Learning to live with the pain: acceptance of pain predicts adjustment in persons with chronic pain. Pain 1998;74:21–7.
13. Vlaeyen JW, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art. Pain 2000;85:317–32.
14. McCracken LM. Behavioral constituents of chronic pain acceptance: results from factor analysis of the chronic pain acceptance questionnaire. J Back Musculoskelet Rehabil 1999; 13. https://doi.org/10.3233/bmr-1999-132-306.
15. Vowles KE, Witkiewitz K, Level I, Sowden G, Ashworth J. Are reductions in pain intensity and pain-related distress necessary? An analysis of within-treatment change trajectories in relation to improved functioning following interdisciplinary acceptance and commitment therapy for adults with chronic pain. J Consult Clin Psychol 2017;85:87–98.
16. Hayes SD, Duckworth MP. Acceptance and commitment therapy and traditional cognitive behavior therapy approaches to pain. Cognit Behav Pract 2006;13:185–7.
17. Thompson M, McCracken LM. Acceptance and related processes in adjustment to chronic pain. Curr Pain Headache Rep 2011;15:144–51.
18. McCracken LM, Vowles KE, Gauntlett-Gilbert J. A prospective investigation of acceptance and control-oriented coping with chronic pain. J Behav Med 2007;30:339–49.
19. Nicholas MK, Asghari A. Investigating acceptance in adjustment to chronic pain: is acceptance broader than we thought? Pain 2006;124:269–79.
20. McCracken LM, Eccleston C. A prospective study of acceptance of pain and patient functioning with chronic pain. Pain 2005;118:164–9.
21. McCracken LM, Vowles KE, Eccleston C. Acceptance of chronic pain: component analysis and a revised assessment method. Pain 2004;107:159–66.
22. McCracken LM, Sperti LS, Janeck AS, Sinclair D, Wetzel FT. Behavioral dimensions of adjustment in persons with chronic pain: pain-related anxiety and acceptance. Pain 1999;80:283–9.
23. McCracken LM, Eccleston C. Coping or acceptance: what to do about chronic pain? Pain 2003;105:197–204.
24. Rodero B, Casanueva B, Luciano JV, Gilli M, Serrano-Blanco A, García-Campayo J. Relationship between behavioural coping strategies and acceptance in patients with fibromyalgia syndrome: Elucidating targets of interventions. BMC Musculoskel Disord 2011;12:143.
25. Yu L, Norton S, Almarzooqi S, McCracken LM. Preliminary investigation of self-as-context in people with fibromyalgia. Br J Pain 2017;11:134–43.
26. Trainer H, Baranoff J, Henke M, Winefield H. Functioning with fibromyalgia: the role of psychological flexibility and general psychological acceptance. Aust Psychol 2019;54:214–24.
27. Lami MJ, Martinez MP, Mliro E, Sanchez Al, Guzman MA. Catastrophizing, acceptance, and coping as mediators between pain and emotional distress and disability in fibromyalgia. J Clin Psychol Med Settings 2018;25:80–92.
28. Kroksstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, et al. Cohort profile: the HUNT study, Norway. Int J Epidemiol 2012;42:968–77.
29. Eide H, Leren L, Sorebo O. The Norwegian versions of the Chronic Pain Acceptance Questionnaire CPAQ-20 and CPAQ-8 - validation and reliability studies. Disabil Rehabil 2017;39:1441–8.
30. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire - development and validation. J Rheumatol 1991; 18:728–33.
31. Williams DA, Arnold LM. Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI-20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self-Report Questionnaire (MASQ). Arthritis Care Res 2011;63: S86–S97.
32. Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005;23 (5 Suppl 39):S154–62.
33. Arnold LM, Lu Y, Crofford LJ, Wohlfrech M, Detke MJ, Lyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974–84.
34. Remé SE, Lie SA, Eriksen HR. Are 2 questions enough to screen for depression and anxiety in patients with chronic low back pain? Spine (Phila Pa 1976) 2014;39:E455–62
35. Fors EA, Sexton H. Weather and the pain in fibromyalgia: are they related?. Ann Rheum Dis 2002;61:247.
36. Vowles KE, McCracken LM, Eccleston C. Processes of change in treatment for chronic pain: the contributions of pain, acceptance, and catastrophizing. Eur J Pain 2007;11:779–87.
37. Viane I, Crombez G, Eccleston C, Poppe C, Devulder J, Van Houdenhove B, et al. Acceptance of pain is an independent predictor of mental well-being in patients with chronic pain: empirical evidence and reappraisal. Pain 2003;106:65–72.
38. Perrot S, Winkelmann A, Dukes E, Xu X, Schaefler C, Ryan K, et al. Characteristics of patients with fibromyalgia in France and Germany. Int J Clin Pract 2010;64:1100–8.
39. Bannwarth B, Blotman F, Roué-Le Lay K, Caubère J-P, André E, Taïeb C. Fibromyalgia syndrome in the general population of France: A prevalence study, Joint Bone Spine 2009;76:184–7.
40. Bennett RM, Jones J, Turk DC, Russell II, Mataliana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskel Disord 2007;8:27.
41. White KP, Speechley M, Harth M, Ostbye T. The London fibromyalgia epidemiology study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999;26:1570–6.
42. Angarita-Osorio N, Pérez-Aranda A, Feliu-Soler A, Andrés-Rodríguez L, Borras X, Suso-Ribera C, et al. Patients with fibromyalgia reporting severe pain but low impact of the syndrome: clinical and pain-related cognitive features. Pain Pract: Off J World Inst Pain 2019;20:255–61.
43. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 2009;36:1304–11.
44. Mundal I, Bjørgaard JH, Nilsen TIL, Nicholl BI, Gråwe RW, Fors EA. Long-term changes in musculoskeletal pain sites in the general population: the HUNT study. J Pain 2016;17:1246–56.
45. Andersson HI. The course of non-malignant chronic pain: a 12-year follow-up of a cohort from the general population. Eur J Pain 2004;8:47–53.
46. Schaefer C, Mann R, Masters ET, Cappelleri JC, Daniel SR, Zlateva G, et al. The comparative burden of chronic widespread pain and fibromyalgia in the United States. Pain Pract 2016;16:565–79.
47. Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 2009;11:R120.
48. Kurtze N, Svebak S. A county population of males given the diagnosis of fibromyalgia syndrome—comparison with fibromyalgia syndrome females regarding pain, fatigue, anxiety, and depression: the Nord-Trøndelag health study [The HUNT Study]. J Musculoskel Pain 2005;13:11–8.
49. Kurtze N, Svebak S. Fatigue and patterns of pain in fibromyalgia: correlations with anxiety, depression and co-morbidity in a female county sample. Br J Med Psychol 2001; 74:523–37.
50. Fors EA, Eide H, Wensaas K-A, Wolfe F, Clauw D. Fibromyalgia 2016 criteria and assessments: comprehensive validation in a Norwegian population. Scand J Pain 2020. https://doi.org/10.1515/sjpain-2020-0002 [Epub ahead of print].
51. Wolfe F, Vailitt B, Perrot S, Rasker JJ, Häuser W. Fibromyalgia diagnosis and biased assessment: sex, prevalence and bias. PloS One 2018;13:e0203755-e. https://doi.org/10.1371/journal.pone.0203755.
52. Haugmark T, Hagen KB, Smedslund G, Zangi HA. Mindfulness- and acceptance-based interventions for patients with fibromyalgia - a systematic review and meta-analyses. PloS one 2019;14:e0221897.
53. Simister HD, Tchachuk GA, Shay BL, Vincent N, Pear JJ, Skrabek RQ. Randomized controlled trial of online acceptance and commitment therapy for fibromyalgia. J Pain 2018;19:741–53.
54. Luciano JV, Guallar JA, Aguado J, Lopez-Del-Hoyo Y, Olivan B, Magallon R, et al. Effectiveness of group acceptance and commitment therapy for fibromyalgia: a 6-month randomized controlled trial (EFFIGACT study). Pain 2014;155:693–702.